A cost-effectiveness modeling study of treatment interventions for stage I to III esophageal squamous cell carcinoma

Daroudi, Rajabali; Nahvijou, Azin; Arab, Mohammad; Faramarzi, Ahmad; Kalaghchi, Bita; Sari, Ali Akbari; Javan-Noughabi, Javad

doi:10.1186/s12962-022-00352-5

Cost Effectiveness and Resource Allocation

Table 1 Model input estimates

From: A cost-effectiveness modeling study of treatment interventions for stage I to III esophageal squamous cell carcinoma

Description	Base case	Range	Reference
Stage I
Esophagectomy
Complication	0.119	0.119–0.35	[33, 34]
Dead	0.055	0.018–0.111	[8, 34]
No recurrence to local recurrence	0.0239	–	[35]
No recurrence to metastasis	0.0139	0.002–0.0139	[35,36,37]
No recurrence to Dead	0.07		[38]
EMR
Complication	0.069	0.030–0.069	[6, 10, 12]
Dead	0	–	[12]
No recurrence to local recurrence	0.0188	0.0076–0.0426	[6, 12, 37, 39]
No recurrence to metastasis	0.0233	–	[37]
No recurrence to dead	0.07	–	[12, 37, 38]
EMR followed by ablation
Complication	0.12	0.068–0.222	[40, 41]
Dead	0		[42]
No recurrence to local recurrence	0.0287	0.014–0.033	[43,44,45]
No recurrence to metastasis	0.0151	–	[45]
No recurrence to dead	0.082	–	[46]
Stage II and III
Esophagectomy
Complication	0.25	0.25–0.39	[35, 47]
Dead	0.06	0.0339–0.111	[8, 48]
No recurrence to local recurrence	0.1085	–	[49]
No recurrence to metastasis	0.0309	–	[49]
No recurrence to dead	0.085	0–0.0905	[47, 49, 50]
CRT followed by surgery
Complication	0.2	0.17–0.289	[11, 51]
Dead	0.06	0.04–0.105	[5, 52]
No recurrence to local recurrence	0.0151	0.003–0.0151	[38, 53]
No recurrence to Metastasis	0.0123	0.0073–0.0123	[53, 54]
No recurrence to Dead	0.08	–	[52, 53]
CRT
Complication	0.17	0.148–0.28	[13, 14]
Dead	0.04	0.024–0.058	[13, 14]
No recurrence to local recurrence	0.0528	0.028–0.0528	[14, 55]
No recurrence to metastasis	0.0139	0.0221–0.0139	[14, 55]
No recurrence to dead	0.13	–	[6, 13, 56]
COST ($ US)
Esophagectomy	3464	–	Health system Iran
EMR	1788	–	Health system Iran
EMR followed by ablation	2136	–	Health system Iran
CRT followed by surgery	4762	–	Health system Iran
CRT	2410	–	Health system Iran
Utility
No esophageal cancer	1	–	Assumption
Stage I esophageal cancer	0.693	0.66–0.71	[57, 58]
Stage II and III esophageal cancer	0.76	0.74–0.78	[57, 58]
Stage IV esophageal cancer	0.75	0.73–0.77	(57, 58)
Death	1	–	Assumpation

Back to article page

ISSN: 1478-7547

Contact us

General enquiries: journalsubmissions@springernature.com